[Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain].
The prevalence of ulcerative colitis (UC) and its associated economic burden is increasing in Spain. Oral mesalazines, which are the recommended first-line treatment for mild-moderate UC, show considerable variability in their formulations and prices. To carry out a cost-effectiveness assessment of the use of the two formulations of oral gastro-resistant modified-release mesalazine formulations marketed in Spain (Salofalk(®) and Mezavant(®)) for the phases of induction of remission and its maintenance. We adapted internationally validated economic models for the management of UC to the Spanish setting. The adaptation focused on the use of oral gastro-resistant modified-release mesalazines. We conducted cost minimization analyses of remission induction (decision tree) and remission maintenance (Markov model). For the remission induction, Salofalk(®) 3 g/day was superior to (same effectiveness at lower costs) Mezavant(®) 3.6 g/day and 4.8 g/day in any treatment strategy that included oral gastro-resistant modified-release mesalazines. When compared with Mezavant(®) 2.4 g/day, Salofalk(®) was the most cost-effective option. For remission maintenance, all treatment strategies using Salofalk(®) were the most cost-effective option in all the scenarios considered. Because of the lower cost per gram of Salofalk(®), any treatment strategy based on this drug is more cost-effective than Mezavant(®) for the treatment of mild-moderate UC, whether for the induction of remission or for its maintenance.